{"entity":{"id":"nct07446387","kind":"trial","name":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer","aka":[],"tldr":"A phase 2 trial of Iparomlimab and tuvonralimab in Colorectal cancer, run by Jiangsu Cancer Institute & Hospital, not yet recruiting.","summary":"A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT07446387 by Jiangsu Cancer Institute & Hospital, with 70 participants planned, started 2026-05-30 and due to reach its primary completion in 2028-12-31. Interventions recorded: Iparomlimab and tuvonralimab. Conditions recorded: Metastatic Colorectal Cancer (CRC).\n\nLinked to the drug Iparomlimab and tuvonralimab because the registry names it among its interventions and Colorectal cancer among its conditions. Registry record only: no result has been read by an editor.","status":"planned","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07446387","url":"https://clinicaltrials.gov/study/NCT07446387"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":["iparomlimab-tuvonralimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07446387","phase":"2","setting":"A Prospective, Single-arm, Multicenter Phase II Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regimen as First-line Treatment for Unresectable Advanced Colorectal Cancer","sponsor":"Jiangsu Cancer Institute & Hospital","participation":[{"nct":"NCT07446387","source":"https://clinicaltrials.gov/study/NCT07446387","fetchedAt":"2026-10-07T16:55:45.930Z","studySha256":"07c3ff6f489d117e5bcff31f0e95f4e2240d3d79544f970d520ffc9111d6eaea","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-05-12","leadSponsor":"Jiangsu Cancer Institute & Hospital","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":70,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":0,"countries":["China"]}],"started":"2026-05-30","startedType":"estimated","enrolled":70,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07446387/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"drug":[{"id":"iparomlimab-tuvonralimab","kind":"drug","name":"Iparomlimab and tuvonralimab","route":"/drugs/iparomlimab-tuvonralimab/"}]}}